Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Fate Therapeutics in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek anticipates that the biopharmaceutical company will post earnings per share of ($0.73) for the year. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.
Several other equities analysts also recently weighed in on the stock. Barclays cut their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating on the stock in a report on Wednesday, May 14th. Wells Fargo & Company cut their price target on shares of Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Wedbush reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research note on Thursday, March 6th. Robert W. Baird dropped their price objective on shares of Fate Therapeutics from $5.00 to $4.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 14th. Finally, Wall Street Zen raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 15th. Eight analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.14.
Fate Therapeutics Stock Down 7.2%
Shares of Fate Therapeutics stock opened at $1.55 on Tuesday. The firm has a market capitalization of $177.64 million, a P/E ratio of -0.94 and a beta of 2.23. The company has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.38. Fate Therapeutics has a 52 week low of $0.66 and a 52 week high of $5.92.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.18 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%.
Hedge Funds Weigh In On Fate Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. American Century Companies Inc. increased its holdings in Fate Therapeutics by 6.6% during the 4th quarter. American Century Companies Inc. now owns 197,704 shares of the biopharmaceutical company’s stock worth $326,000 after purchasing an additional 12,295 shares during the last quarter. SG Americas Securities LLC increased its holdings in Fate Therapeutics by 30.6% during the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 10,511 shares during the last quarter. Hsbc Holdings PLC increased its holdings in Fate Therapeutics by 22.0% during the 4th quarter. Hsbc Holdings PLC now owns 109,422 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 19,706 shares during the last quarter. Millennium Management LLC increased its holdings in Fate Therapeutics by 28.9% during the 4th quarter. Millennium Management LLC now owns 413,192 shares of the biopharmaceutical company’s stock worth $682,000 after purchasing an additional 92,576 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Fate Therapeutics by 154.2% during the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 20,805 shares during the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Read More
- Five stocks we like better than Fate Therapeutics
- Investing In Automotive Stocks
- Is Consumer Discretionary a Dead End? These 3 Stocks Say No
- What is MarketRank™? How to Use it
- Why a Trump-Musk Feud Could Mean Big Wins for AST SpaceMobile
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Nintendo Stock Near Highs—Will the Switch 2 Keep the Rally Alive?
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.